Exagen Q3 rev $13.4M, net loss narrows to $5.4M; guides FY rev at least $50M

EXAGEN INC.

2023-Q3 EPS reported -$1.03 revenue$38,783,000

Revenue $13.4M vs $14.7M YoY (included $3.7M one-time Medicare); net loss $(5.4)M vs $(8.1)M.
Adj. EBITDA improved to $(3.6)M from $(6.1)M YoY; gross margin 57.4% vs 59.2%.
Cash $28.4M at Sep 30, $31.4M at Oct 31; AVISE CTD ASP $320.
FY 2023 guidance: rev ≥$50M (record), adj. EBITDA ~$(20)M; expects improvement in 2024.
Exclusive license with Johns Hopkins to develop lupus nephritis biomarkers.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXAGEN INC. reported the three and nine months ended September 30, 2023 results: revenue $13.4 million, net income $(5.4) million. Guidance reaffirmed.

Period: the three and nine months ended September 30, 2023
Revenue: $13.4 million
Net income: $(5.4) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2023. • Recognized total revenue of $13.4 million for the third quarter of 2023. • Delivered gross margin of 57.4% for the third quarter of 2023. • AVISE® CTD trailing twelve-month average selling price (ASP) of $320. • Net loss

View on SEC.gov

Browse all earnings releases →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-23-000101

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.